These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 26652184

  • 1. Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma.
    Cornelissen R, Hegmans JP, Maat AP, Kaijen-Lambers ME, Bezemer K, Hendriks RW, Hoogsteden HC, Aerts JG.
    Am J Respir Crit Care Med; 2016 May 01; 193(9):1023-31. PubMed ID: 26652184
    [Abstract] [Full Text] [Related]

  • 2. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
    Hegmans JP, Veltman JD, Lambers ME, de Vries IJ, Figdor CG, Hendriks RW, Hoogsteden HC, Lambrecht BN, Aerts JG.
    Am J Respir Crit Care Med; 2010 Jun 15; 181(12):1383-90. PubMed ID: 20167848
    [Abstract] [Full Text] [Related]

  • 3. Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human.
    Aerts JGJV, de Goeje PL, Cornelissen R, Kaijen-Lambers MEH, Bezemer K, van der Leest CH, Mahaweni NM, Kunert A, Eskens FALM, Waasdorp C, Braakman E, van der Holt B, Vulto AG, Hendriks RW, Hegmans JPJJ, Hoogsteden HC.
    Clin Cancer Res; 2018 Feb 15; 24(4):766-776. PubMed ID: 29233904
    [Abstract] [Full Text] [Related]

  • 4. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells.
    Hegmans JP, Hemmes A, Aerts JG, Hoogsteden HC, Lambrecht BN.
    Am J Respir Crit Care Med; 2005 May 15; 171(10):1168-77. PubMed ID: 15764728
    [Abstract] [Full Text] [Related]

  • 5. Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy.
    Noordam L, Kaijen MEH, Bezemer K, Cornelissen R, Maat LAPWM, Hoogsteden HC, Aerts JGJV, Hendriks RW, Hegmans JPJJ, Vroman H.
    Oncoimmunology; 2018 May 15; 7(12):e1474318. PubMed ID: 30524884
    [Abstract] [Full Text] [Related]

  • 6. Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS.
    de Goeje PL, Klaver Y, Kaijen-Lambers MEH, Langerak AW, Vroman H, Kunert A, Lamers CHJ, Aerts JGJV, Debets R, Hendriks RW.
    Front Immunol; 2018 May 15; 9():2034. PubMed ID: 30245692
    [Abstract] [Full Text] [Related]

  • 7. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
    de Boer NL, van Kooten JP, Burger JWA, Verhoef C, Aerts JGJV, Madsen EVE.
    BMJ Open; 2019 May 14; 9(5):e026779. PubMed ID: 31092657
    [Abstract] [Full Text] [Related]

  • 8. Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial.
    Ellebaek E, Engell-Noerregaard L, Iversen TZ, Froesig TM, Munir S, Hadrup SR, Andersen MH, Svane IM.
    Cancer Immunol Immunother; 2012 Oct 14; 61(10):1791-804. PubMed ID: 22426890
    [Abstract] [Full Text] [Related]

  • 9. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.
    Höltl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, Nussbaumer W, Falkensammer C, Bartsch G, Thurnher M.
    Cancer Immunol Immunother; 2005 Jul 14; 54(7):663-70. PubMed ID: 15918076
    [Abstract] [Full Text] [Related]

  • 10. Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.
    Lievense LA, Bezemer K, Cornelissen R, Kaijen-Lambers ME, Hegmans JP, Aerts JG.
    Lung Cancer; 2017 May 14; 107():36-40. PubMed ID: 27168021
    [Abstract] [Full Text] [Related]

  • 11. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission.
    Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH.
    Cancer Immunol Immunother; 2012 May 14; 61(5):629-41. PubMed ID: 22021066
    [Abstract] [Full Text] [Related]

  • 12. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.
    Alfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, Martin-Algarra S, Calvo A, Redrado M, Agliano A, Gonzalez A, Rodriguez I, Bolaños E, Hervás-Stubbs S, Perez-Calvo J, Benito A, Peñuelas I, Vigil C, Richter J, Martinez-Forero I, Melero I.
    J Immunol; 2011 Dec 01; 187(11):6130-42. PubMed ID: 22048768
    [Abstract] [Full Text] [Related]

  • 13. Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.
    Dammeijer F, Lievense LA, Kaijen-Lambers ME, van Nimwegen M, Bezemer K, Hegmans JP, van Hall T, Hendriks RW, Aerts JG.
    Cancer Immunol Res; 2017 Jul 01; 5(7):535-546. PubMed ID: 28536100
    [Abstract] [Full Text] [Related]

  • 14. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D, Blondy T, Deshayes S, Dehame V, Bertrand P, Grégoire M, Errami M, Blanquart C.
    Clin Epigenetics; 2018 Jul 01; 10():79. PubMed ID: 29946373
    [Abstract] [Full Text] [Related]

  • 15. Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors.
    Minatel E, Trovo M, Bearz A, Di Maso M, Baresic T, Drigo A, Barresi L, Furlan C, Del Conte A, Bruschi G, Fontana P, Pagan V, Franchin G.
    Int J Radiat Oncol Biol Phys; 2015 Nov 01; 93(3):606-13. PubMed ID: 26281826
    [Abstract] [Full Text] [Related]

  • 16. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients.
    Rodríguez-Ruiz ME, Perez-Gracia JL, Rodríguez I, Alfaro C, Oñate C, Pérez G, Gil-Bazo I, Benito A, Inogés S, López-Diaz de Cerio A, Ponz-Sarvise M, Resano L, Berraondo P, Barbés B, Martin-Algarra S, Gúrpide A, Sanmamed MF, de Andrea C, Salazar AM, Melero I.
    Ann Oncol; 2018 May 01; 29(5):1312-1319. PubMed ID: 29554212
    [Abstract] [Full Text] [Related]

  • 17. High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment.
    Parisi E, Romeo A, Sarnelli A, Ghigi G, Bellia SR, Neri E, Micheletti S, Dipalma B, Arpa D, Furini G, Burgio MA, Genestreti G, Gurioli C, Sanna S, Bovolato P, Rea F, Storme G, Scarpi E, Arienti C, Tesei A, Polico R.
    Cancer Radiother; 2017 Dec 01; 21(8):766-773. PubMed ID: 29132803
    [Abstract] [Full Text] [Related]

  • 18. Enhanced dendritic cell-based immunotherapy using low-dose cyclophosphamide and CD25-targeted antibody for transplanted Lewis lung carcinoma cells.
    Son CH, Bae JH, Lee HR, Shin DY, Yang K, Park YS.
    J Immunother; 2015 Apr 01; 38(3):107-15. PubMed ID: 25751500
    [Abstract] [Full Text] [Related]

  • 19. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
    Inogés S, Tejada S, de Cerio AL, Gállego Pérez-Larraya J, Espinós J, Idoate MA, Domínguez PD, de Eulate RG, Aristu J, Bendandi M, Pastor F, Alonso M, Andreu E, Cardoso FP, Valle RD.
    J Transl Med; 2017 May 12; 15(1):104. PubMed ID: 28499389
    [Abstract] [Full Text] [Related]

  • 20. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, Pezzuto F, Pavan A, Vuljan SE, Del Bianco P, Conte P, Rea F, Calabrese F.
    Ann Oncol; 2018 May 01; 29(5):1258-1265. PubMed ID: 29514216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.